Redefining Precision Oncology with Next-Generation ADCs
Our Solution: Next-Generation ADC Platform
Proprietary AI Platform
Human Expertise
TargetAppy
AI-driven target discovery & prioritization
Multi-omics integration (transcriptomic, proteomic, single cell, spatial)
Tumor-specific, internalizing antigens + filtering & scoring
DrugAppy
Computational chemistry for rational drug design
Virtual docking, MD simulations & generative AI
Optimized payloads, linkers & conjugation strategies
AI + scientific supervision to ensure reliable outputs
By rethinking both what we target and how we deliver therapeutics, C-Therapeutics is creating a new generation of cancer treatments.
If you are interested in learning more about our scientific work, do not hesitate to contact us.
News & Scientific Papers
Nobel Prize Awarded for Pioneering Work in Neural Networks
On October 8, 2024, Geoffrey Hinton, alongside John J. Hopfield, was awarded the Nobel Prize in Physics for their groundbreaking contributions to artificial neural network machine learning. Their pioneering discoveries have revolutionized the field of AI, enabling...
MAT2A and PRMT5: Key Cancer Targets Gaining Attention
MAT2A and PRMT5 have emerged as critical cancer targets, with about 15% of all tumors showing MTAP depletion—a number that can increase to 30% after chemotherapy. Despite their promise, developing MAT2A inhibitors has proven challenging for many companies, with...
Understanding cancer with interspeaces genomic evaluation
This paper is about the genome of the Greenland shark (Somniosus microcephalus) and its insights into extreme longevity, including chromosome-level assembly, genetic adaptations, and unique traits.
Contact
C-Therapeutics part of TMCi ACT program – Cohor 2025
2450 Holcombe Blvd., Suite X, Gate 2450
Houston, TX 77021, United States
BD Office
85 Swanson Rd #293,
Boxborough, MA 01719
bd@ctherapeuticsgroup.com